Heska (NASDAQ:HSKA) Shares Gap Up Following Insider Buying Activity

Shares of Heska Co. (NASDAQ:HSKAGet Rating) gapped up before the market opened on Tuesday following insider buying activity. The stock had previously closed at $67.31, but opened at $69.92. Heska shares last traded at $73.77, with a volume of 121 shares changing hands.

Specifically, CEO Kevin S. Wilson purchased 11,018 shares of the business’s stock in a transaction that occurred on Friday, January 6th. The shares were acquired at an average price of $58.62 per share, for a total transaction of $645,875.16. Following the completion of the acquisition, the chief executive officer now directly owns 167,072 shares in the company, valued at approximately $9,793,760.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Kevin S. Wilson purchased 11,018 shares of the business’s stock in a transaction that occurred on Friday, January 6th. The shares were acquired at an average price of $58.62 per share, for a total transaction of $645,875.16. Following the completion of the acquisition, the chief executive officer now directly owns 167,072 shares in the company, valued at approximately $9,793,760.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin S. Wilson purchased 3,440 shares of the business’s stock in a transaction that occurred on Thursday, December 22nd. The stock was bought at an average price of $59.64 per share, for a total transaction of $205,161.60. Following the acquisition, the chief executive officer now owns 156,054 shares of the company’s stock, valued at $9,307,060.56. The disclosure for this purchase can be found here. 11.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on HSKA shares. Piper Sandler dropped their target price on shares of Heska from $170.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, November 14th. Alliance Global Partners dropped their target price on shares of Heska from $155.00 to $119.00 and set a “buy” rating on the stock in a report on Wednesday, November 9th. JPMorgan Chase & Co. dropped their target price on shares of Heska from $175.00 to $150.00 and set an “overweight” rating on the stock in a report on Monday, October 17th. Morgan Stanley cut shares of Heska from an “equal weight” rating to an “underweight” rating and set a $58.00 target price on the stock. in a report on Friday, January 6th. Finally, StockNews.com started coverage on shares of Heska in a report on Wednesday, October 12th. They set a “hold” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $123.00.

Heska Trading Up 9.0 %

The firm has a 50-day moving average price of $64.88 and a 200-day moving average price of $77.77. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.61 and a current ratio of 7.18. The stock has a market cap of $794.30 million, a PE ratio of -46.73 and a beta of 1.40.

Heska (NASDAQ:HSKAGet Rating) last posted its quarterly earnings results on Tuesday, November 8th. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.15. The firm had revenue of $61.49 million during the quarter, compared to analyst estimates of $69.72 million. Heska had a positive return on equity of 0.09% and a negative net margin of 6.26%. As a group, equities analysts anticipate that Heska Co. will post 0.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Heska

Several large investors have recently modified their holdings of the stock. Lazard Asset Management LLC purchased a new position in Heska in the 2nd quarter worth about $39,000. Point72 Hong Kong Ltd purchased a new position in Heska in the 1st quarter worth about $57,000. Quantbot Technologies LP raised its position in Heska by 245.6% in the 3rd quarter. Quantbot Technologies LP now owns 508 shares of the medical research company’s stock worth $37,000 after buying an additional 361 shares during the last quarter. UBS Group AG raised its position in Heska by 83.1% in the 3rd quarter. UBS Group AG now owns 1,703 shares of the medical research company’s stock worth $124,000 after buying an additional 773 shares during the last quarter. Finally, Mutual of America Capital Management LLC raised its position in Heska by 17.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 1,812 shares of the medical research company’s stock worth $171,000 after buying an additional 269 shares during the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Heska Company Profile

(Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.

See Also

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.